What 9 Analyst Ratings Have To Say About Instructure Holdings
Analysts have provided the following ratings for Instructure Holdings (NYSE:INST) within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago
34 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 139% to $8.18 after surging over 15% on Tuesday.
Morgan Stanley Maintains Equal-Weight on Instructure Holdings, Raises Price Target to $25
Morgan Stanley analyst Josh Baer maintains Instructure Holdings (NYSE:INST) with a Equal-Weight and raises the price target from $24 to $25.
Instructure Holdings Q2 EPS $(0.17) Up From $(0.61) YoY, Sales $93.57M Up From $61.37M YoY
Instructure Holdings (NYSE:INST) reported quarterly losses of $(0.17) per share. This is a 72.13 percent increase over losses of $(0.61) per share from the same period last year. The company reported $93.57 million in
Macquarie Initiates Coverage On Instructure Holdings with Outperform Rating, Announces Price Target of $26
Macquarie analyst Sarah Hindlian initiates coverage on Instructure Holdings (NYSE:INST) with a Outperform rating and announces Price Target of $26.
Earnings Scheduled For August 17, 2021
Companies Reporting Before The Bell
• AiHuiShou Intl (NYSE:RERE) is expected to report earnings for its second quarter.
JP Morgan Initiates Coverage On Instructure Holdings with Overweight Rating, Announces Price Target of $24
JP Morgan analyst Sterling Auty initiates coverage on Instructure Holdings (NYSE:INST) with a Overweight rating and announces Price Target of $24.
William Blair Initiates Coverage On Instructure Holdings with Outperform Rating
William Blair analyst Stephen Sheldon initiates coverage on Instructure Holdings (NYSE:INST) with a Outperform rating.